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ABSTRACT
Background: Benzodiazepines are drugs widely used for the treatment of anxiety and insomnia. The pre-
sent study has analysed the prescriptions of this class of drugs among sailing seafarers, to evaluate the 
appropriateness of prescribed therapies.
Materials and methods: This study assessed the benzodiazepine prescriptions made by Centro Internazio-
nale Radio Medico (CIRM) doctors from 2011 to 2015. A total of 17,844 medical records were examined. 
Analysis considered the prescriptions of benzodiazepines in monotherapy, or in association with other 
drugs. Diagnoses of pathologies for which benzodiazepines were prescribed were made according to the 
ICD-10 classification system proposed by the World Health Organisation.
Results: Among medical records analysed, benzodiazepines were prescribed in 765 cases (3.29% of total 
cases assisted by CIRM). Benzodiazepines were prescribed as a single-drug treatment in 626 (81.83%) 
cases, whereas in 139 cases they were associated with other classes of drugs. In case of opioids prescri-
bed in association with benzodiazepines, the drug used was codeine. This therapeutic association was 
prescribed in cases of severe pain.
Conclusions: Although the “off label” use of benzodiazepines is not uncommon in medical practice, clear 
evidence indicates their potential side effects for human health. In this respect, medical professionals should 
comply with international guidelines on the use of benzodiazepines, both when prescribed as a single drug 
or in combination with other classes of drugs. These recommendations should be considered seriously in 
case of limited medical facilities such as on board of sailing ships.
(Int Marit Health 2018; 69, 1: 28–34)
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INTRODUCTION
Benzodiazepines are the most frequently prescribed 
drugs after cardiovascular medications [1]. The effective-
ness of the benzodiazepines exceeds the placebo in con-
trolling a wide range of anxiety related symptoms [2, 3] and 
reducing the onset of insomnia [4]. The use of benzodiaze-
pines for long periods can induce dependence, abuse and 
symptoms of withdrawal [5, 6]. Based on these risks, several 
guidelines have warned against the use of benzodiazepines 
for long periods, especially in older population [7]. 
The use of benzodiazepines in a multidrug therapy, in 
particular with opioids, may cause respiratory depression 
[8]. Concurrent use of oxycodone and benzodiazepines may 
lead to increased inhibition of the central nervous system 
and respiratory system [9]. Clinical guidelines from the 
United States Centres for Disease Control and Prevention 
recommend the utmost caution in combining opioids and 
benzodiazepines to avoid possible consequences [10].
In this study we analysed the prescriptions of benzo-
diazepines among patients on board commercial vessels 
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without a  doctor, and assisted by Centro Internazionale 
Radio Medico (International Radio Medical Centre [CIRM]). 
CIRM is the Italian Telemedical Maritime Assistance Service 
(TMAS) and the Centre with the largest experience in the 
field, worldwide [11]. In this work, prescriptions of benzo-
diazepines among seafarers assisted by CIRM from 2011 
to 2015 were analysed. Prescriptions were divided into 
single-drug prescriptions (benzodiazepines were the only 
prescribed drug) and multi-drug prescriptions (benzodiaze-
pines in association with other medicines). 
Seafarers represent a category of workers particularly 
exposed to physical and mental stress. For such a reason 
we decided to evaluate the appropriateness of benzodiaze-
pine prescriptions among them, and to assess the effective 
compliance of the advice with standard pharmacotherapy 
guidelines.
MATERIALS AND METHODS
This study analysed benzodiazepine prescriptions 
performed by CIRM physicians from 1st January 2011 to 
31st December 2015. For each case assisted by the Centre, 
a digitalised medical file is established and updated after 
any contact with the ship. These files represented the basis 
of this study. 
All seafarers gave their informed consent for the treat-
ment of their medical data by CIRM. According to the 
informed consent policy, data were anonymised before 
being used for research purposes. This survey is a part of 
the project called “Health Protection and Safety on Board 
Ships” (acronym: HEALTHY SHIP). It is a project of disease 
prevention and health protection approved by the CIRM 
Foundation Ethic Committee [12].
The investigation was performed by reviewing 17,844 
health records of patients assisted by CIRM during the 
period indicated above. Among these, 632 were excluded 
because they were related to advice on hygiene or pharma-
cy management. The remaining 17,212 medical records 
were considered for this study and the diagnosis of CIRM 
physicians was classified according to the International 
Classification of Diseases, 10th edition (ICD-10) [8]. This 
standard is used worldwide for the general epidemiology, 
health management and clinical analysis. 
After this first evaluation, medical files containing ben-
zodiazepine prescriptions were extrapolated and examined. 
Considering the different clinical implications that a multi-
drug therapy with benzodiazepines may involve (compared 
to a single-drug therapy), cases in which benzodiazepines 
were the only drug prescribed were extrapolated from cases 
in which benzodiazepines were prescribed in combination 
with other classes of drugs.
The demographic data of the people assisted and receiv-
ing benzodiazepine prescriptions were considered. Our sam-
ple consisted for the most part of male subjects employed 
on board merchant ships aged between 18 and 64 years 
(mean 38.5 ± 11.6 years). A small percentage (52 cases) 
was represented by women and children. They did not have 
benzodiazepines prescribed. Analysis did not consider the 
rank of people receiving benzodiazepine prescription or the 
flag of the ship where they worked.  
In a second step, the prescriptions of benzodiazepines 
were compared to the diagnosis of the problem for which 
they were given. This was done in order to evaluate the 
compliance of the prescription with guidelines for their use.
RESULTS
Benzodiazepine prescribed for pathologies classified 
according to the ICD-10 are summarised in Table 1.  
As shown, benzodiazepines were prescribed in 765 cas-
es (3.29% of total cases assisted by CIRM). Benzodiazepines 
were prescribed as a single-drug treatment in 626 cases 
(81.83%), whereas in 139 cases they were associated with 
other therapeutic agents (Table 2). As shown in Table 2, 
benzodiazepines were more often associated with opioids 
(16.8%), followed by non-steroidal anti-inflammatory drugs 
(NSAID) (Table 2).
Analysis of benzodiazepine prescriptions (as a mono-
therapy) during the 5 years of observation has shown 
a significant increase in their number from 2011 to 2012. 
Prescriptions of benzodiazepines plateauned from 2012 
to 2014 and then slightly decreased (Fig. 1). Analysis of 
prescriptions of benzodiazepines in combination with other 
classes of drugs is summarised in Table 2.
As shown the most common association was with co-
deine followed in descending order by different NSAID (e.g. 
acetylsalicylic acid, ibuprofen, diclofenac and nimesulide) 
and by paracetamol.
Prescriptions of benzodiazepines in association with 
codeine were analysed carefully in view of the risks of 
combining these drugs [10]. In the first year of observation 
(2011), the drug combination of diazepam and codeine 
was found 123 times (Fig. 2). In the subsequent years the 
prescription rate of this association dropped to 0 (Fig. 2).
Analysis of prescriptions of benzodiazepines according to 
diagnosis showed that for the ICD-10 class V diseases (men-
tal and behavioural disorders) we had 111 benzodiazepine 
prescriptions (89 in single drug therapy and 22 in association 
with codeine) (Fig. 3). This accounts for the 64.53% of cases 
diagnosed with this class of diseases (Table 1). Pathologies 
for which benzodiazepines were prescribed included anxiety 
(36 cases), depression (27 cases), psychomotor agitation 
(21 cases) and behavioural disorders (19 cases).
For class VI (diseases of the nervous system) ben-
zodiazepines were prescribed in 110 cases (99 in sin-
gle-prescription, 8 associated with codeine and 3 as-
Int Marit Health 2018; 69, 1: 28–34
www.intmarhealth.pl30
Table 1. Diagnosis (ICD-10) of diseases for which benzodiazepines were prescribed from 2011–2015
ICD-10 Total  
cases 
assisted
No. of cases  
with benzodiazepi- 
nes prescriptions
Per cent
I. Certain infectious and parasitic diseases 670 3 0.45%
II. Neoplasms 2 0 0%
III. Diseases of the blood and blood-forming organs  
and certain disorders involving the immune mechanism
60 0 0%
IV. Endocrine, nutritional and metabolic diseases 172 3 1.74%
V. Mental and behavioural disorders 172 111 64.53%*
VI. Diseases of the nervous system 577 110 19.065*
VII. Diseases of the eye and adnexa 639 3 0.47%
VIII. Diseases of the ear and mastoid process 231 3 1.30%
IX. Diseases of the circulatory system 1227 279 22.74%*
X. Diseases of the respiratory system 885 15 1.70%
XI. Diseases of the digestive system 3261 43 1.32%
XII. Diseases of the skin and subcutaneous tissue 1690 9 0.53%
XIII. Diseases of the musculoskeletal system and connective tissue 1243 51 4.10%
XIV. Diseases of the genitourinary system 1595 20 1.25%
XV. Pregnancy, childbirth and the puerperium 52 0 0%
XVI. Certain conditions originating in the perinatal period 0 0 0%
XVII. Congenital malformations, deformations and  
chromosomal abnormalities
15 1 Not quantifiable  
for insufficient  
number of cases
XVIII. Symptoms, signs and abnormal clinical and laboratory findings,  
not elsewhere classified
1279 74 5.79%*
XIX. Injury, poisoning and certain other consequences of external causes 3207 37 1.15%
XX. External causes of morbidity and mortality 58 0 0%
XXI. Factors influencing health status and contact with health services 177 3 1.69%
*Asterisk indicates classes of pathologies with the larger use of benzodiazepine prescriptions.
Table 2. Different benzodiazepines prescribed in monotherapy 
and in association with other therapeutic agents
Benzodiazepine molecule prescribed N (%)
Diazepam 622 (81.31%)
Nitrazepam 2 (0.26%)
Alprazolam 1 (0.13%)
Clonazepam 1 (0.13%)
Benzodiazepines in association N (%)
Diazepam + codeine 123 (16.08%)
Diazepam + acetylsalicylic acid 8 (1.05%)
Diazepam + paracetamol (acetaminophen) 3 (0.39%)
Diazepam + ibuprofen 3 (0.39%)
Diazepam + diclofenac 1 (0.13%)
Diazepam + nimesulide 1 (0.13%)
Data were derived from analysis of the 765 clinical records using benzodiazepines.
sociated with NSAIDs) (Fig. 3). Hence benzodiazepines 
were prescribed in the 19.06% of cases of this class of 
disease (Table 1).
Figure 3 summarises the different ICD-10 classes of 
diseases for which benzodiazepine were prescribed alone 
in combination. Disease categories for which benzodiaze-
pines were highly prescribed are highlighted in red with an 
asterisk in Table 1.
For class IX ICD-10 (diseases related to the cardiovas-
cular system) benzodiazepines were prescribed 241 times 
(225 in monotherapy, 50 in combination with codeine 
and 4 in association with NSAIDs) (Fig. 3). In summary, 
benzodiazepines were given to 22.74% of cases of these 
class of diseases (Table 1). Pathologies for which ben-
zodiazepines were mostly prescribed included arterial 
hypertension (131 cases), precordial pain (122 cases) 
and tachycardia (13 cases). 
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Figure 1. Time-course of single-drug prescriptions of benzodiazepines
Figure 2. Time-trend of prescriptions of benzodiazepines in multi-
drug therapies; NSAIDs — non-steroidal anti-inflammatory drugs
Figure 3. Benzodiazepine prescriptions in single-drug and in combination therapies, in the different classes of diseases for which there 
drugs were mainly used; NSAIDs — non-steroidal anti-inflammatory drugs
For class XIII (diseases of the musculoskeletal system 
and connective tissue) the total percentage of benzodiaz-
epines averaged the 4.10% (51 prescriptions of benzodi-
azepines) (Table 1). In this class of diseases benzodiaz-
epines were prescribed as a  single-drug in 41 cases, 
7 times in association with opioids and 3 times in association 
with NSAIDs (Fig. 3). Prescriptions were for low back pain 
(31 cases) and neck pain (14 cases). 
For the ICD-10 class XVIII (symptoms, signs and abnormal 
clinical and laboratory findings, not elsewhere classified) 
the percentage of total prescriptions of benzodiazepines 
averaged to 5.79% (Table 1), with a total of 74 prescriptions 
of benzodiazepines (56 single-drug therapy, 15 in combina-
tion with codeine and 3 in association with NSAIDs) (Fig. 3). 
Weakness and fatigue (63 cases) were the main reason for 
prescribing benzodiazepines in this class of diseases.
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DISCUSSION
The analysis of data revealed a common trend of benzo-
diazepine prescriptions among seafarers. Despite the risks 
associated with the use of this class of drugs (falls [13], 
fractures, accidents at work [14–19]), the utilisation of ben-
zodiazepines increased during the 5 years of observation, 
with an estimated increase of more than 400% between 
2011 and 2012, an increase less pronounced in 2013 and 
a slight decline in 2014 and 2015 (Fig. 1). Anxiety (36%) and 
insomnia (44%) represented the most common diagnoses 
for the prescription of benzodiazepines [20–22]. Clinical 
guidelines recommend that benzodiazepines and other 
hypnotics should only be used in short-term treatment for se-
vere insomnia and only be used after careful consideration 
of the non-pharmacological options such as behavioural 
interventions like sleep education, stimulus control [23]. 
New guidelines recommend newer anti-depressants [24], in 
substitution of benzodiazepines for the primary treatment of 
anxiety disorders [25]. Although many physicians are aware 
of the indications and warnings provided by the guidelines 
that warn against the unjustified use of benzodiazepines, 
in particular in long-term therapy, a few of them believe that 
this practice constitutes a serious risk for their patients [26]. 
The problem of pharmacological treatment of patients 
and diseases on board ships is complex for several reasons. 
The first is that, as already mentioned in the introduction, 
with the exception of cruise ships or large passenger ships 
in some countries, other merchant ships do not carry on 
board neither doctors nor other qualified health profes-
sionals. Treatment of diseases or accidents is left to the 
responsibility of the captain who could be supported by 
TMAS [27, 28]. However, even more recent international rec-
ommendations leave to the captain the final responsibility of 
choices or of treatment [28]. A principle rather questionable 
taking into account the rudimental medical knowledge of 
a ship’s captain [29, 30]. The second is the limited avail-
ability of medicinal products carried on board ships. Every 
ship, even small ships and those covering short distances, 
should have a minimum supply of medicinal products and 
medication items that constitute the so-called ship’s med-
icine chest [27]. The World Health Organisation [31], the 
European Economic Community [32] and the main maritime 
countries have regulated the contents of ship’s medicine 
chest. These may differ considerably in the number and 
typology of medicinal products and other supplies. This may 
limit the prescription of effective treatments normally used 
by a doctor. Hence, apparent inappropriate prescriptions 
may depend by the lack of availability on board of the most 
appropriate medicinal products. 
Diseases of cardiovascular system (ICD-10 class IX) were 
those for which benzodiazepines were more prescribed 
from a quantitative point of view, followed by mental and 
behavioural disorders (ICD-10 class V), symptoms, signs 
and abnormal clinical and laboratory findings (ICD-10 class 
XVIII), diseases of the musculoskeletal system (ICD-10 class 
XIII) and of the nervous system (ICD-10 class VI). In terms 
of percentage of benzodiazepine prescriptions referred to 
the number of patients suffering from a given class of dis-
eases, benzodiazepines were given more often for mental 
and behavioural disorders, followed by diseases of the cir-
culatory system, nervous system, symptoms and diseases 
of the musculoskeletal system. The main ICD-10 classes in 
which benzodiazepines were prescribed in monotherapy or 
in association; during the period under study were classes V, 
VI, IX, XIII and XVIII. 
In class V, mental and behavioural disorders, benzo-
diazepines were mainly used for anxiety, depression, psy-
chomotor agitation and behavioural disorders. Often due to 
lack of more specific drugs, aboard ships, for depressive 
disorders, the use of anxiolytics in depressive disorders 
continues to be of interest, since depression has a close 
relationship with anxiety [33]. 
In class VI, diseases of the nervous system, benzo-
diazepines were mostly used to treat insomnia, sciatica, 
headache, epileptic seizure and paraesthesia. 
Data of class IX (diseases of the circulatory system) 
show the wide (over 100 cases) use of benzodiazepines in 
the treatment of hypertension and precordial pain. In this 
respect, it has been reported that benzodiazepines have 
hypotensive action through a central mechanism that acts 
on arterial baroreflex or the sympathetic and vagal outflow. 
Other researchers attribute the hypotensive action of ben-
zodiazepines to their vasodilatatory effect or its effect on 
peripheral benzodiazepine receptors, suggesting a periph-
eral mechanism [34, 35].
In class XIII, diseases of the musculoskeletal system 
and connective tissue, benzodiazepines are mostly used for 
low back and neck pain. GABAergic compounds enhance 
endogenous inhibitory control within the central nervous 
system and are therefore potentially useful in human pain 
conditions. In particular, a study showed the analgesic effect 
of clobazam in low back pain [36]. 
Finally, in class XVIII, symptoms, signs and abnormal 
clinical and laboratory findings, not elsewhere classified, 
we observed a  high use of benzodiazepines in cases of 
weakness and fatigue. This is interesting, as weakness and 
fatigue are common adverse effects of benzodiazepines. 
Probably, in this case, the use of benzodiazepines was 
related with their sedative effects, which could result in the 
promotion of rest and subsequent recovery of the patient. 
Anyhow, the appropriateness of this use may be questioned, 
and it is another example of how the lack of more specific 
drugs in the ship’s pharmacy can determine the prescription 
of second-choice treatments.
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Clinical guidelines from the United States Centres for 
Disease Control and Prevention, suggest the utmost cau-
tion concerning the concurrent use of opioids and ben-
zodiazepines, to avoid possible serious consequences 
[8, 10]. In this study, it was observed that between 2011 and 
2012 treatment with diazepam in combination with codeine 
was prescribed 123 times (Fig. 2). In subsequent years, 
from 2013 to 2015, this drug combination was no longer 
prescribed. The use of this drug combination was mainly 
prescribed for diseases of class IX (diseases of the cardio-
vascular system) with a total number of 42 prescriptions, 
24 prescriptions for class V (diseases related to mental and 
behavioural disorders), 21 prescriptions for class XVIII (dis-
eases diagnosed by symptoms, signs and abnormal clinical 
and laboratory tests, diseases that can’t be classified in 
other classes) and 12 prescriptions for class XIII (diseas-
es related to the musculoskeletal system and connective 
tissue (Fig. 3). The ship’s medicine chest often lacks of in 
specific drugs, primarily whose indicated for certain classes 
of less considered. This could explain the “off label” use of 
benzodiazepines on board ships.
CONCLUSIONS
Although the “off label” use of benzodiazepines is re-
flected in medical practice, clear scientific evidence exists 
for potential side effects of these drugs for human health. 
In this respect, medical professionals should rigidly comply 
with international guidelines in the use of benzodiazepines, 
both when prescribed as a single drug or in combination 
with other classes of drugs. Real-time monitoring pro-
grammes can help physicians to make more appropriate 
decisions when prescribing this sensitive class of drugs. 
A review of the regulations on drugs and medicines that 
commercial ships should carry expanding medical chests 
based on the actual incidence rates of on-board condi-
tions would allow doctors to have a wider choice in the 
prescribing pharmacological treatments. The safe use of 
benzodiazepines in the ship’s  environment, where any 
intervention reducing concentration and alertness could 
be risky will be possible if seafarers, their doctors, ship 
owners, and international organisations will work together 
and act balancing advantages and potential problems in 
the use of this class of drugs.
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